Is the CSL share price set to take off in December?

The future looks bright for this ASX 200 healthcare giant.

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price could be in for a good run in the near future
  • Many brokers are tipping it to soar as much as 14% amid the launch of its Hemgenix gene therapy
  • Meanwhile, others are bullish on the healthcare sector more broadly

The CSL Limited (ASX: CSL) share price leapt 7% in November, and December looks like it could bring more joy. Experts are generally bullish on the Aussie biotechnology giant.

Particularly on the back of the company's Hemgenix treatment, which recently received US Food and Drug Administration (FDA) approval. The gene therapy is designed to treat hemophilia B.

It has also reportedly been crowned the world's most expensive treatment. A single dose is said to command a US$3.5 million price tag.

Right now, the CSL share price is $299.72.

Let's take a look at what brokers are saying about the S&P/ASX 200 Index (ASX: XJO) healthcare giant.

What might the future hold for the CSL share price?

CSL appears to be a favourite among brokers and experts right now, with some predicting its share price to leap as high as $343.

That's the prediction put forward by Macquarie, as my Fool colleague James reports. The top broker has a buy rating on the stock and expects Hemgenix's early 2023 launch to boost the company's earnings.

Citi is also hopeful for CSL, slapping the share with a buy rating and a $340 price target.

Not all brokers are so enthusiastic, however. Goldman Sachs' most recent forecast, from early November, tips the CSL share price to fall to $291.

It's worth noting that experts apparently aren't tipping the company's bottom line to be immediately buoyed by Hemgenix's launch. Indeed, CSL chief commercial officer Bill Campbell recently told investors "it will take a little bit of time for questions to be answered in the commercial space", the Australian Financial Review reports.

Looking beyond CSL and to the healthcare sector more broadly, Janus Henderson portfolio manager Andy Acker recently wrote, per Livewire:

[E]ven if major economies enter a recession in 2023, we believe the healthcare sector could offer investors some safe harbour. In the past, the sector has outperformed in the months leading up to and during economic downturns; the same could hold true again.

Additionally, Morgans equity analyst Anna Milne is said to like the prospects of the company's Seqirus vaccine in the upcoming flu season and its recently-acquired Vifor iron deficiency therapy business. Morgans expects the CSL share price to lift to $327, according to Livewire.

All in all, many experts appear to believe December could be a good time to buy CSL stock ahead of an expected share price surge.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »